Chances are your company’s research and development pipeline includes several PROTAC candidates — placing you with many others in the race to bring successful and efficient protein degraders to the clinic. The majority of these candidates aim at undruggable cancer targets usually involved in signal transduction, transcription regulation, scaffolding, etc.
These targets also present challenges in the biophysical characterization of the binary and ternary complex interactions, making developing effective degraders much more complicated — and potentially leaving your company lagging behind your competitors.
Watch this on-demand webinar to learn how Dianthus — a plate-based affinity screening platform with breakthrough Spectral Shift technology — overcomes the challenges for the biophysical characterization of binary and ternary complexes of 5 PROTACs against cancer target WD-Repeat-Containing Protein 5 (WDR5).
